

**Audiência Pública:
A Conscientização sobre
Doenças Valvares Cardíacas**


Valvopatia Mitral

José A. Mangione, Phd, FESC, FACC

- Diretor de Equipe de Cardiologia Intervencionista BP/SP
- Cardiologista Intervencionista do Hospital Alemão Oswaldo Cruz
- Professor Livre Docente pela Universidade de São Paulo (USP)
- Presidente da Sociedade Latino Americana de Cardiologia Intervencionista (SOLACI)

Doença Valvar


Incidência



Mitral regurgitation (MR) affects almost 10% of the population aged 75 and over

European Heart Survey


Insuficiência Mitral Sintomática



50% of the patients with severe symptomatic MR are denied surgery

Insuficiência Mitral Funcional Severa Não Operada

Evolução Clínica




n = 577 MR \geq 3+

Cleveland Clinic

n = 462 (ICC) Universidade de Modena e Bolonha

INSUFICIÊNCIA MITRAL
SECUNDÁRIA


GRAVIDADE VS
MORTALIDADE



Insuficiência Mitral

Taxa de Hospitalização

Pacientes com insuficiência mitral grave apresentam uma taxa de internação hospitalar significativamente maior por insuficiência cardíaca




Seguimento Clínico ~ 7 anos (n =218 casos pareados 1:1)

Insuficiência Mitral Primária Grave

Fisiopatologia e História Natural



A intervenção precoce pode resultar em excelentes desfechos a longo prazo na IM primária




MIDA TRIAL

Tratamento Cirúrgico IM Degenerativa

n = 1.912 6 Centros (Europa e EUA) Seguimento Clínico Médio – 9,2 anos





Tratamiento Cirúrgico



Técnica de Alfieri

J Thorac Cardiovasc Surg 2001;122:674-81

MITRACLIP COMPONENTES DO SISTEMA

CLIP DE CROMO E COBALTO
REVESTIDO COM POLYESTER






MITRACLIP


Características

MITRACLIP


Indicações



Normal




Prolapso



Ruptura de Cordoalha

Flail





Isquêmica ou Idiopática

Primária/Degenerativa


Secundária/Funcional

Punção Transeptal


Ecocardiograma



Avaliação da Insuficiência Mitral




Intercomissural




Eixo Longo

Avaliação da Insuficiência Mitral – Eco 3D




Localização



Largura do Flail


Grasp dos Folhetos

Projeção LVOT



EVEREST TRIAL II

Sobrevida – 5 anos



MITRACLIP

Comparação dos Estudos

	EVEREST II (n = 184)	ACCESS-EU (n = 567)	Transcatheter Valve Treatment Sentinel Pilot Registry (n = 628)	TRAMI (prospective cohort) (n = 749)
Hospital stay (days)	NA	7.7 ± 8.2 (median: 6.0)	5.0 [3.0–7.0]	9.0 [6.0–15.0]
Procedural success (Clip implanted + MR ≤2+/not severe)	137/178 (77.0%)	516/567 (91.0%)	599/628 (95.4%)	719/741 (97.0%)
Mitral regurgitation at discharge, n (%)				
None/mild	NA	NA	268/368 (72.8%)	631/741 (85.2%)
Moderate	NA	NA	93/368 (25.3%)	93/741 (12.6%)
Severe	NA	NA	7/368 (1.9%)	17/741 (2.3%)

1 ano

Additional MV procedure, n (%)	37/181 (21%)	55/567 (9.7%)	17/444 (3.8%)	37/436 (8.5%)
Surgical	37/181 (21%)	36/567 (6.3%)	4/444 (0.9%)	10/436 (2.3%)
Percutaneous	0/181 (0%)	19/567 (3.4%)	13/444 (2.9%)	23/436 (5.2%)

Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip: five-year German national patient sample including 13,575 implants

